Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.